Analyst Price Targets — ALXO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 11:47 am | — | Piper Sandler | $4.00 | $2.01 | TheFly | ALX Oncology price target raised to $4 from $3 at Piper Sandler |
| March 7, 2025 2:18 pm | — | Stifel Nicolaus | $1.50 | $1.06 | TheFly | ALX Oncology price target lowered to $1.50 from $3 at Stifel |
| June 10, 2024 8:47 am | Colin Bristow | UBS | $25.00 | $8.83 | StreetInsider | UBS Reiterates Buy Rating on ALX Oncology (ALXO) |
| June 3, 2024 8:43 am | Christopher Raymond | Raymond James | $21.00 | $9.10 | StreetInsider | Piper Sandler Reiterates Overweight Rating on ALX Oncology (ALXO) |
| April 10, 2024 12:29 pm | Bradley Canino | Stifel Nicolaus | $14.00 | $11.85 | StreetInsider | Stifel on ALX Oncology (ALXO): 'our Hold thesis is based on the lack of development strategy clarity in these opportunities' |
| August 9, 2022 10:00 am | — | Credit Suisse | $38.00 | $11.77 | Benzinga | Credit Suisse Maintains Outperform on ALX Oncology Holdings, Lowers Price Target to $38 |
| June 13, 2022 7:55 am | Bradley Canino | Stifel Nicolaus | $16.00 | $6.79 | Pulse 2.0 | ALX Oncology (ALXO) Stock Price: $16 Target And Buy Rating |
Latest News for ALXO
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of…
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph. D. , After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer…
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALXO.
U.S. House Trading
No House trades found for ALXO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.